EE200200555A - Farmatseutiliselt aktiivsed pürrolidiini derivaadid - Google Patents

Farmatseutiliselt aktiivsed pürrolidiini derivaadid

Info

Publication number
EE200200555A
EE200200555A EEP200200555A EEP200200555A EE200200555A EE 200200555 A EE200200555 A EE 200200555A EE P200200555 A EEP200200555 A EE P200200555A EE P200200555 A EEP200200555 A EE P200200555A EE 200200555 A EE200200555 A EE 200200555A
Authority
EE
Estonia
Prior art keywords
pharmaceutically active
pyrrolidine derivatives
active pyrrolidine
derivatives
pharmaceutically
Prior art date
Application number
EEP200200555A
Other languages
English (en)
Inventor
Halazy Serge
Schwarz Matthias
Quattropani Anna
Thomas Russel
Baxter Anthony
Scheer Alexander
Original Assignee
Applied Research Systems Ars Holding N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems Ars Holding N.V. filed Critical Applied Research Systems Ars Holding N.V.
Publication of EE200200555A publication Critical patent/EE200200555A/et

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
EEP200200555A 2000-03-27 2001-03-20 Farmatseutiliselt aktiivsed pürrolidiini derivaadid EE200200555A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00106034 2000-03-27
PCT/EP2001/003171 WO2001072705A1 (en) 2000-03-27 2001-03-20 Pharmaceutically active pyrrolidine derivatives as bax inhibitors

Publications (1)

Publication Number Publication Date
EE200200555A true EE200200555A (et) 2004-06-15

Family

ID=8168169

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200555A EE200200555A (et) 2000-03-27 2001-03-20 Farmatseutiliselt aktiivsed pürrolidiini derivaadid

Country Status (33)

Country Link
US (2) US7211601B2 (et)
EP (1) EP1268419B1 (et)
JP (2) JP2003528854A (et)
KR (1) KR100714585B1 (et)
CN (1) CN1296354C (et)
AR (1) AR029499A1 (et)
AT (1) ATE330940T1 (et)
AU (2) AU5620901A (et)
BG (1) BG107132A (et)
BR (1) BR0109900A (et)
CA (1) CA2401242A1 (et)
CY (1) CY1105519T1 (et)
CZ (1) CZ20023243A3 (et)
DE (1) DE60120940T2 (et)
DK (1) DK1268419T3 (et)
EA (1) EA006424B1 (et)
EE (1) EE200200555A (et)
ES (1) ES2261404T3 (et)
HK (1) HK1054031B (et)
HR (1) HRP20020705A2 (et)
HU (1) HUP0300994A2 (et)
IL (1) IL151912A0 (et)
MX (1) MXPA02009382A (et)
NO (1) NO323969B1 (et)
NZ (1) NZ521060A (et)
PL (1) PL358001A1 (et)
PT (1) PT1268419E (et)
SI (1) SI1268419T1 (et)
SK (1) SK13832002A3 (et)
UA (1) UA74362C2 (et)
WO (1) WO2001072705A1 (et)
YU (1) YU73502A (et)
ZA (1) ZA200206799B (et)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001252222B2 (en) * 2000-03-27 2006-11-02 Merck Serono Sa Pharmaceutically active pyrrolidine derivatives as bax inhibitors
CN100564378C (zh) * 2001-06-18 2009-12-02 雪兰诺实验室有限公司 吡咯烷噁二唑及噻二唑衍生物
AR034897A1 (es) 2001-08-07 2004-03-24 Hoffmann La Roche Derivados n-monoacilados de o-fenilendiaminas, sus analogos heterociclicos de seis miembros y su uso como agentes farmaceuticos
US7030141B2 (en) * 2001-11-29 2006-04-18 Christopher Franklin Bigge Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
US7405234B2 (en) 2002-05-17 2008-07-29 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
UA78058C2 (en) * 2002-07-05 2007-02-15 Applied Research Systems Pyrrolidine derivative as oxitocin antagonists
US7632858B2 (en) * 2002-11-15 2009-12-15 Bristol-Myers Squibb Company Open chain prolyl urea-related modulators of androgen receptor function
ATE449067T1 (de) * 2003-02-27 2009-12-15 Merck Serono Sa Pyrrolidin-derivate als oxytocin antagonisten
US7820702B2 (en) 2004-02-04 2010-10-26 Bristol-Myers Squibb Company Sulfonylpyrrolidine modulators of androgen receptor function and method
ES2296137T3 (es) * 2004-02-26 2008-04-16 Laboratoires Serono Sa Metodo para preparar pirrolidin-oximas.
US7625923B2 (en) 2004-03-04 2009-12-01 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
US7696241B2 (en) 2004-03-04 2010-04-13 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
CA2746943A1 (en) * 2008-12-18 2010-07-15 Boehringer Ingelheim International Gmbh Serotonin 5-ht2b receptor inhibitors
JP6043290B2 (ja) 2011-09-22 2016-12-14 武田薬品工業株式会社 縮合複素環化合物
EP2845850A1 (en) 2013-09-10 2015-03-11 ObsEva S.A. Pyrrolidine derivatives as oxytocin/vasopressin V1a receptors antagonists
EP2886107A1 (en) 2013-12-17 2015-06-24 ObsEva S.A. Oral formulations of pyrrolydine derivatives
AU2015283133B2 (en) 2014-07-02 2019-05-16 ObsEva SA Crystalline (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime useful in methods of treating conditions related to the OT-R activity
CN114621962A (zh) * 2022-03-21 2022-06-14 广西大学 花生AhBI-1基因VIGS沉默体系
CN117044622A (zh) * 2023-09-22 2023-11-14 贵州师范大学 一种无花瓣芥菜型油菜的选育方式

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL33548A (en) 1964-08-05 1972-04-27 Upjohn Co Galactopyranosides which are intermediates for lincomycin
US3555007A (en) 1968-07-22 1971-01-12 Upjohn Co 7-deoxy-7-halo lincomycin d derivatives
US3674647A (en) 1970-10-07 1972-07-04 Upjohn Co Preparation of lincomycin analogues
US4596819A (en) * 1984-01-23 1986-06-24 Warner-Lambert Company Modified tripeptides
GB9316162D0 (en) 1993-08-04 1993-09-22 Zeneca Ltd Fungicides
WO1996022775A1 (en) 1995-01-24 1996-08-01 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
US5756497A (en) 1996-03-01 1998-05-26 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
AR016133A1 (es) * 1997-07-31 2001-06-20 Wyeth Corp Compuesto de carbamiloxi que inhiben la adhesion de leucocitos mediada por vla-4, compuestos que son prodrogas de dichos compuestos, composicionfarmaceutica, metodo para fijar vla-4 a una muestra biologica, metodo para el tratamiento de una condicion inflamatoria
US6329418B1 (en) * 1998-04-14 2001-12-11 The Procter & Gamble Company Substituted pyrrolidine hydroxamate metalloprotease inhibitors
EP1097929A4 (en) * 1998-07-14 2005-12-21 Ono Pharmaceutical Co AMINO ACID DERIVATIVES AND MEDICAMENTS IN WHICH THESE DERIVATIVES ARE THE ACTIVE INGREDIENTS
IL141063A (en) * 1998-08-07 2005-06-19 Applied Research Systems Derivatives of pyrrolidine-2-carboxylic acid and piperidine-2-carboxylic acids and pharmaceutical compositions comprising said derivatives for treating infertility
IL144577A0 (en) * 1999-01-27 2002-05-23 Ortho Mcneil Pharm Inc Peptidyl heterocyclic ketones useful as tryptase inhibitors
CA2362290A1 (en) * 1999-02-18 2000-08-24 Kaken Pharmaceutical Co., Ltd. Novel amide derivatives as growth hormone secretagogues
BR0009043A (pt) * 1999-03-15 2002-01-08 Axys Pharm Inc Composto, composição farmacêutica, e, método de tratar uma doença em um animal em que a atividade da cisteìna protease contribui para a patologia e/ou sintomatologia da doença
US6333344B1 (en) * 1999-05-05 2001-12-25 Merck & Co. Prolines as antimicrobial agents
GB0000079D0 (en) * 2000-01-05 2000-02-23 Ferring Bv Novel antidiuretic agents
AU2001252222B2 (en) * 2000-03-27 2006-11-02 Merck Serono Sa Pharmaceutically active pyrrolidine derivatives as bax inhibitors

Also Published As

Publication number Publication date
KR20020095195A (ko) 2002-12-20
PL358001A1 (en) 2004-08-09
JP2003528854A (ja) 2003-09-30
PT1268419E (pt) 2006-08-31
DE60120940D1 (de) 2006-08-03
HK1054031A1 (en) 2003-11-14
AU5620901A (en) 2001-10-08
DE60120940T2 (de) 2007-01-25
BG107132A (bg) 2003-04-30
HRP20020705A2 (en) 2004-12-31
JP5580364B2 (ja) 2014-08-27
CN1419541A (zh) 2003-05-21
EA200201026A1 (ru) 2003-02-27
EP1268419A1 (en) 2003-01-02
CA2401242A1 (en) 2001-10-04
MXPA02009382A (es) 2003-01-28
NO20024598L (no) 2002-11-25
DK1268419T3 (da) 2006-10-02
ES2261404T3 (es) 2006-11-16
SK13832002A3 (sk) 2003-03-04
US20030212012A1 (en) 2003-11-13
NO20024598D0 (no) 2002-09-25
AU2001256209B2 (en) 2006-02-16
CN1296354C (zh) 2007-01-24
CZ20023243A3 (cs) 2003-01-15
NZ521060A (en) 2004-05-28
WO2001072705A1 (en) 2001-10-04
ATE330940T1 (de) 2006-07-15
YU73502A (sh) 2005-11-28
ZA200206799B (en) 2003-08-26
US7211601B2 (en) 2007-05-01
HUP0300994A2 (hu) 2003-08-28
BR0109900A (pt) 2003-06-03
NO323969B1 (no) 2007-07-23
EP1268419B1 (en) 2006-06-21
AR029499A1 (es) 2003-07-02
US20080167318A1 (en) 2008-07-10
UA74362C2 (uk) 2005-12-15
JP2012149098A (ja) 2012-08-09
SI1268419T1 (sl) 2006-10-31
HK1054031B (zh) 2007-05-04
KR100714585B1 (ko) 2007-05-07
EA006424B1 (ru) 2005-12-29
IL151912A0 (en) 2003-04-10
CY1105519T1 (el) 2010-07-28

Similar Documents

Publication Publication Date Title
PT1220856E (pt) Compostos farmaceuticamente activos
DK1218374T3 (da) Farmaceutisk aktive sulfonamidderivater
EE200000438A (et) Farmatseutiliselt aktiivne morfolinool
NO20021400D0 (no) Terapeutiske konazolinderivater
DK1292604T3 (da) 2-Aminocarbonyl-9H-purinderivater
EE200300175A (et) Tsüanopürrolidiini derivaadid
ATE540013T1 (de) Naphthalinderivate
NO20015664D0 (no) Nye farmasöytisk aktive forbindelser
EE200200555A (et) Farmatseutiliselt aktiivsed pürrolidiini derivaadid
NO20025729D0 (no) Etylendicystein(EC)-medikament konjugater
ATE288437T1 (de) Tetrahydro-heterocycloazepinyl-pyrimidin-deriva e
ATE298332T1 (de) Decahydro-isochinolinderivate
DK1280809T3 (da) Antitumorecteinascidinderivater
DK1322593T3 (da) O-substituerede-6-methyl-tramadol-derivater
DE59902159D1 (de) Aktiver mikromischer
DK1246791T3 (da) Aminomethyl-phenyl-cyklohexanonderivater
DE60045878D1 (de) Pharmazeutisch aktive Isoindolin-Derivate
ATE374776T1 (de) Pyrrolotriazolopyrimidinonderivate
NO20024393D0 (no) 2-fenylpyran-4-on-derivater
SE0000645D0 (sv) New pharmaceutically active compounds
SE9901854D0 (sv) New pharmaceutically active compounds
SE0004458D0 (sv) Pharmaceutically useful compounds
SE0002921D0 (sv) Pharmaceutically useful compounds
SI1341537T1 (sl) Farmacevtsko ucinkoviti derivati izoindolina
GB0018660D0 (en) Pharmaceutically active compounds